HCPCS Level II · Drugs administered other than oral method
J0895Injection, deferoxamine mesylate, 500 mg
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J0895
J0895 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, deferoxamine mesylate, 500 mg.
It was added to HCPCS effective 01/01/1992, and its current record took effect 01/01/2001.
Its Medicare coverage code is "D", meaning special Medicare coverage instructions apply.
Details
- Short description
- Deferoxamine mesylate inj
- Date added
- 01/01/1992
- Action effective
- 01/01/2001
- BETOS
- O1E
Related J08xx codes
- J0801Injection, corticotropin (acthar gel), up to 40 units
- J0802Injection, corticotropin (ani), up to 40 units
- J0834Injection, cosyntropin, 0.25 mg
- J0840Injection, crotalidae polyvalent immune fab (ovine), up to 1 gram
- J0841Injection, crotalidae immune f(ab')2 (equine), 120 mg
- J0850Injection, cytomegalovirus immune globulin intravenous (human), per vial
- J0870Injection, imetelstat, 1 mg
- J0871Injection, daptomycin (endo), not therapeutically equivalent to j0878, 1 mg
- J0872Injection, daptomycin (xellia), unrefrigerated, not therapeutically equivalent to j0878 or j0873, 1 mg
- J0873Injection, daptomycin (xellia), not therapeutically equivalent to j0878 or j0872, 1 mg
- J0874Injection, daptomycin (baxter), not therapeutically equivalent to j0878, 1 mg
- J0875Injection, dalbavancin, 5 mg
Common questions about J0895
Is HCPCS J0895 still valid?
- Yes. J0895 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J0895?
- Its coverage code is "D": special Medicare coverage instructions apply. Check the local coverage determination for your region.